$PRPH
ProPhase Labs, Inc.

2014 Q4 Form 10-Q Financial Statement

#000114420414067701 Filed on November 13, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q3
Revenue $8.972M $5.130M $5.949M
YoY Change -6.56% -13.77% 9.86%
Cost Of Revenue $3.080M $1.620M $2.132M
YoY Change 1.99% -24.02% 5.54%
Gross Profit $5.896M $3.510M $3.817M
YoY Change -10.49% -8.04% 12.3%
Gross Profit Margin 65.72% 68.42% 64.16%
Selling, General & Admin $6.160M $2.792M $2.397M
YoY Change 7.32% 16.48% 10.97%
% of Gross Profit 104.48% 79.54% 62.8%
Research & Development $420.0K $356.0K $181.0K
YoY Change 75.0% 96.69% 6.47%
% of Gross Profit 7.12% 10.14% 4.74%
Depreciation & Amortization $80.00K $70.00K $60.00K
YoY Change 33.33% 16.67% -14.29%
% of Gross Profit 1.36% 1.99% 1.57%
Operating Expenses $6.570M $6.725M $2.578M
YoY Change 10.05% 160.86% 11.12%
Operating Profit -$674.0K -$3.215M $1.239M
YoY Change -209.24% -359.48% 14.83%
Interest Expense $0.00 $2.000K $3.000K
YoY Change -100.0% -33.33%
% of Operating Profit 0.24%
Other Income/Expense, Net
YoY Change
Pretax Income -$680.0K -$3.216M $1.236M
YoY Change -213.33% -360.19% 15.51%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings -$676.0K -$3.216M $1.237M
YoY Change -213.23% -359.98% 15.18%
Net Earnings / Revenue -7.53% -62.69% 20.79%
Basic Earnings Per Share -$0.18 $0.08
Diluted Earnings Per Share -$44.04K -$176.8K $0.08
COMMON SHARES
Basic Shares Outstanding 15.46M shares 18.21M shares 15.86M shares
Diluted Shares Outstanding 18.21M shares 16.31M shares

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.930M $4.950M $750.0K
YoY Change 78.66% 560.0% -58.79%
Cash & Equivalents $2.926M $4.953M $751.0K
Short-Term Investments
Other Short-Term Assets $1.400M $2.250M $2.110M
YoY Change -22.22% 6.64% 91.82%
Inventory $3.292M $4.180M $3.273M
Prepaid Expenses
Receivables $5.836M $4.051M $4.445M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $13.46M $15.44M $10.58M
YoY Change 19.32% 45.91% 0.66%
LONG-TERM ASSETS
Property, Plant & Equipment $2.599M $2.484M $2.511M
YoY Change 1.37% -1.08% 2.49%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $2.599M $2.484M $6.088M
YoY Change -57.68% -59.2% 1.13%
TOTAL ASSETS
Total Short-Term Assets $13.46M $15.44M $10.58M
Total Long-Term Assets $2.599M $2.484M $6.088M
Total Assets $16.06M $17.92M $16.67M
YoY Change -7.82% 7.52% 0.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $667.0K $2.108M $1.298M
YoY Change -34.03% 62.4% 140.37%
Accrued Expenses $3.690M $3.170M $2.690M
YoY Change 29.47% 17.84% -52.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.241M $7.182M $4.741M
YoY Change 13.34% 51.49% -28.6%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $100.0K $200.0K $300.0K
YoY Change -50.0% -33.33%
Total Long-Term Liabilities $100.0K $200.0K $300.0K
YoY Change -50.0% -33.33%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.241M $7.182M $4.741M
Total Long-Term Liabilities $100.0K $200.0K $300.0K
Total Liabilities $5.341M $7.380M $5.041M
YoY Change 10.72% 46.4% -24.08%
SHAREHOLDERS EQUITY
Retained Earnings -$13.22M -$12.54M -$5.983M
YoY Change 145.48% 109.64%
Common Stock $54.68M $53.82M $43.25M
YoY Change 25.35% 24.46%
Preferred Stock
YoY Change
Treasury Stock (at cost) $30.74M $30.74M $25.64M
YoY Change 19.91% 19.91%
Treasury Stock Shares 9.233M shares 9.233M shares 5.336M shares
Shareholders Equity $10.72M $10.54M $11.63M
YoY Change
Total Liabilities & Shareholders Equity $16.06M $17.92M $16.67M
YoY Change -7.82% 7.52% 0.83%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q3
OPERATING ACTIVITIES
Net Income -$676.0K -$3.216M $1.237M
YoY Change -213.23% -359.98% 15.18%
Depreciation, Depletion And Amortization $80.00K $70.00K $60.00K
YoY Change 33.33% 16.67% -14.29%
Cash From Operating Activities -$1.740M -$2.440M -$3.260M
YoY Change -302.33% -25.15% 21.19%
INVESTING ACTIVITIES
Capital Expenditures -$190.0K -$40.00K -$70.00K
YoY Change 58.33% -42.86% -30.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $10.00K
YoY Change
Cash From Investing Activities -$190.0K -$40.00K -$70.00K
YoY Change 58.33% -42.86% -30.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -100.0K 80.00K 20.00K
YoY Change -166.67% 300.0%
NET CHANGE
Cash From Operating Activities -1.740M -2.440M -3.260M
Cash From Investing Activities -190.0K -40.00K -70.00K
Cash From Financing Activities -100.0K 80.00K 20.00K
Net Change In Cash -2.030M -2.400M -3.310M
YoY Change -328.09% -27.49% 18.64%
FREE CASH FLOW
Cash From Operating Activities -$1.740M -$2.440M -$3.260M
Capital Expenditures -$190.0K -$40.00K -$70.00K
Free Cash Flow -$1.550M -$2.400M -$3.190M
YoY Change -258.16% -24.76% 23.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013 prph Settlement Benefit
SettlementBenefit
100000 USD
CY2013Q4 prph Additional Royalties And Commissions Accrual Interest Percentage
AdditionalRoyaltiesAndCommissionsAccrualInterestPercentage
0.0325 pure
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
324000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
122000 USD
CY2014Q3 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
356000 USD
CY2014Q3 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
1125000 USD
CY2014Q3 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
356000 USD
CY2014Q3 us-gaap Contractual Obligation Due In Fourth Year
ContractualObligationDueInFourthYear
0 USD
CY2014Q3 us-gaap Contractual Obligation Due In Fifth Year
ContractualObligationDueInFifthYear
0 USD
CY2014Q3 us-gaap Contractual Obligation
ContractualObligation
1837000 USD
CY2012 us-gaap Payments For Legal Settlements
PaymentsForLegalSettlements
2100000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt 0.5in"> <b><i><font style="FONT-SIZE: 10pt">Use of Estimates</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements and the accompanying notes thereto, in conformity with GAAP, requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the respective reporting periods. Examples include the provision for bad debt, sales returns and allowances, inventory obsolescence, useful lives of property and equipment and intangible assets, impairment of property and equipment and intangible assets, income tax valuations and assumptions related to accrued advertising. When providing for the appropriate sales returns, allowances, cash discounts and cooperative incentive promotion costs (&#8220;Sales Allowances&#8221;), we apply a uniform and consistent method for making certain assumptions for estimating these provisions. These estimates and assumptions are based on historical experience, current trends and other factors that management believes to be relevant at the time the financial statements are prepared. Management reviews the accounting policies, assumptions, estimates and judgments on a quarterly basis. Actual results could differ from those estimates.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in" align="justify"><font style="FONT-SIZE: 10pt">Our primary product, Cold-EEZE</font><sup style="font-style:normal"><font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt">&#210;</font></sup><sup style="font-style:normal"><font style="FONT-SIZE: 10pt"></font></sup><font style="FONT-SIZE: 10pt">Cold Remedy lozenges, utilizes a proprietary zinc gluconate formulation which has been clinically proven to reduce the severity and duration of common cold symptoms. Factors considered in estimating the appropriate sales returns and allowances for this product include it being (i) a unique product with limited competitors, (ii) competitively priced, (iii) promoted, (iv) unaffected for remaining shelf-life as there is no product expiration date and (v) monitored for inventory levels at major customers and third-party consumption data. In addition to Cold-EEZE<sup style="font-style:normal">&#174;</sup> Cold Remedy lozenges, we market and distribute a variety of Cold-EEZE<sup style="font-style:normal">&#174;</sup> Cold Remedy QuickMelts<sup style="font-style:normal">&#174;</sup> and a Cold-EEZE<sup style="font-style:normal">&#174;</sup> Cold Remedy Oral Spray. We also manufacture, market and distribute an organic cough drop and a Vitamin C supplement (&#8220;Organix<sup style="font-style:normal">&#174;</sup>&#8221;). Each of the Cold-EEZE<sup style="font-style:normal">&#174;</sup> Cold Remedy Oral Spray and QuickMelts<sup style="font-style:normal">&#174;</sup> products, and Organix<sup style="font-style:normal">&#174;</sup> products carry shelf-life expiration dates for which we aggregate such new product market experience data and update our sales returns and allowances estimates accordingly. Sales allowances estimates are tracked at the specific customer and product line levels and are tested on an annual historical basis, and reviewed quarterly. Additionally, we monitor current developments by customer, market conditions and any other occurrences that could affect the expected provisions relative to net sales for the period presented.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><b><i><font style="FONT-SIZE: 10pt">Concentration of Risks</font></i></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in" align="justify"><font style="FONT-SIZE: 10pt">Future revenues, costs, margins, and profits will continue to be influenced by our ability to maintain our manufacturing availability and capacity together with our marketing and distribution capabilities and the regulatory requirements associated with the development of OTC and other personal care products in order to compete on a national level and/or international level.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in" align="justify"><font style="FONT-SIZE: 10pt">Our business is subject to federal and state laws and regulations adopted for the health and safety of users of our products. Our OTC cold remedy <sup style="font-style:normal"></sup>products are subject to regulations by various federal, state and local agencies, including the Food and Drug Administration (&#8220;FDA&#8221;) and, as applicable, the Homeopathic Pharmacopoeia of the United States.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in" align="justify"><font style="FONT-SIZE: 10pt">Financial instruments that potentially subject us to significant concentrations of credit risk consist principally of cash investments and trade accounts receivable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in" align="justify"><font style="FONT-SIZE: 10pt">We maintain cash and cash equivalents with certain major financial institutions. As of September 30, 2014, our cash balance was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.9</font> million and our bank balance was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.0</font> million. Of the total bank balance, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">577,000</font> was covered by federal depository insurance and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4.5</font> million was uninsured at September 30, 2014.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><b><font style="FONT-SIZE: 10pt"> &#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in" align="justify"><font style="FONT-SIZE: 10pt">Trade accounts receivable potentially subject us to credit concentrations from time-to-time as a consequence of the timing, payment pattern and ultimate purchase volumes or shipping schedules with our customers. We extend credit to our customers based upon an evaluation of the customer&#8217;s financial condition and credit history and generally we do not require collateral. Our broad range of customers includes many large national chain, regional, specialty and local retail stores. These credit concentrations may impact our overall exposure to credit risk, either positively or negatively, in that our customers may be similarly affected by changes in economic, regulatory or other conditions that may impact the timing and collectability of amounts due to us. At September 30, 2014 and December 31, 2013, our largest accounts receivable balances are with three customers representing approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 51</font>% and two customers representing <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 46</font>%, respectively, of our total trade receivable balance. As a consequence of an evaluation of our customer&#8217;s financial condition, payment patterns, balance due us and other factors, we did not offset our account receivable with an allowance for bad debt at September 30, 2014 and December 31, 2013.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.5in" align="justify"><b><font style="COLOR: blue; FONT-SIZE: 10pt"> &#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in" align="justify"><font style="FONT-SIZE: 10pt">Our revenues are principally generated from the sale of OTC cold remedy products which represented approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 95</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 91</font>% of total revenues for each of the nine months ended September 30, 2014 and 2013, respectively. A significant portion of our business is highly seasonal, which causes major variations in operating results from quarter to quarter. The third and fourth quarters generally represent the largest sales volume for the OTC cold remedy products. For the three and nine months ended September 30, 2014 and 2013, our net sales were principally related to domestic markets.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
577000 USD
CY2014Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
4500000 USD
CY2014Q3 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
1800000 USD
CY2014Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2400000 USD
CY2014Q3 us-gaap Due From Banks
DueFromBanks
5000000 USD
CY2013 us-gaap Sales Allowances Goods
SalesAllowancesGoods
128000 USD
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
5900000 USD
CY2014Q3 prph Prepaid Advertising And Incentive Promotions
PrepaidAdvertisingAndIncentivePromotions
1900000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
146000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
191000 USD
CY2014Q3 prph Dilutive Securities Options Earnings Share
DilutiveSecuritiesOptionsEarningsShare
0 shares
prph Dilutive Securities Options Earnings Per Share
DilutiveSecuritiesOptionsEarningsPerShare
0
prph Dilutive Securities Options Earnings Per Share
DilutiveSecuritiesOptionsEarningsPerShare
0
CY2013 prph Additional Royalties And Commissions Payable Installment Amount
AdditionalRoyaltiesAndCommissionsPayableInstallmentAmount
100000 USD
CY2012Q4 prph Additional Royalties And Commissions Payable Installment Amount
AdditionalRoyaltiesAndCommissionsPayableInstallmentAmount
100000 USD
CY2014Q3 prph Additional Annual Installment Includes In Other Current Liability
AdditionalAnnualInstallmentIncludesInOtherCurrentLiability
100000 USD
CY2013Q4 prph Additional Annual Installment Includes In Other Long Term Obligation
AdditionalAnnualInstallmentIncludesInOtherLongTermObligation
200000 USD
CY2013 us-gaap Litigation Settlement Interest
LitigationSettlementInterest
13000 USD
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4953000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1638000 USD
CY2014Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4051000 USD
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5319000 USD
CY2014Q3 us-gaap Inventory Net
InventoryNet
4180000 USD
CY2013Q4 us-gaap Inventory Net
InventoryNet
2521000 USD
CY2014Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2252000 USD
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1801000 USD
CY2014Q3 us-gaap Assets Current
AssetsCurrent
15436000 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
11279000 USD
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2484000 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2564000 USD
CY2014Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
0 USD
CY2013Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
3577000 USD
CY2014Q3 us-gaap Assets
Assets
17920000 USD
CY2013Q4 us-gaap Assets
Assets
17420000 USD
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2108000 USD
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1011000 USD
CY2014Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
3166000 USD
CY2013Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
2847000 USD
CY2014Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1908000 USD
CY2013Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
766000 USD
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7182000 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4624000 USD
CY2014Q3 us-gaap Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
200000 USD
CY2013Q4 us-gaap Liabilities Other Than Longterm Debt Noncurrent
LiabilitiesOtherThanLongtermDebtNoncurrent
200000 USD
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
12000 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
11000 USD
CY2014Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
53811000 USD
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
43607000 USD
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-12543000 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5385000 USD
CY2014Q3 us-gaap Treasury Stock Value
TreasuryStockValue
30742000 USD
CY2013Q4 us-gaap Treasury Stock Value
TreasuryStockValue
25637000 USD
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
10538000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
12596000 USD
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17920000 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17420000 USD
prph Equity Method Investment Ownership Percentage Required For Rights Exercisable Under Right Agreement
EquityMethodInvestmentOwnershipPercentageRequiredForRightsExercisableUnderRightAgreement
0.15 pure
prph Cash Less Exercise Of Right Terms
CashLessExerciseOfRightTerms
In the event of a cashless exercise of the Right and the acquirer has acquired less than 50% beneficial ownership of the Company
prph Share Based Compensation Arrangement By Share Based Payment Option Expiration Terms
ShareBasedCompensationArrangementByShareBasedPaymentOptionExpirationTerms
No incentive stock option could be exercisable more than ten years after the date of grant or five years after the date of grant where the individual owns more than ten percent of the total combined voting power of all classes of stock. Stockholders approved the 1997 Plan in Fiscal 1998.
CY2014Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
45
prph Percentage Of Discount On Exercise Of Right
PercentageOfDiscountOnExerciseOfRight
0.5 pure
CY2010 prph Payments To Fund Joint Venture Investments
PaymentsToFundJointVentureInvestments
500000 USD
CY2010 prph Maximum Amount Committed Towards Contributions In Joint Venture
MaximumAmountCommittedTowardsContributionsInJointVenture
2000000 USD
CY2010 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
3600000 USD
CY2010 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P12Y6M
CY2010 prph Ownership Percentage In Joint Venture
OwnershipPercentageInJointVenture
0.5 pure
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-193000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7158000 USD
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1236000 USD
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3216000 USD
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15819000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17216000 shares
CY2013Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15860000 shares
CY2014Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18208000 shares
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
CY2013Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.08
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
prph Dilutive Securities Options Earnings Per Share Value
DilutiveSecuritiesOptionsEarningsPerShareValue
0 USD
prph Dilutive Securities Options Earnings Per Share Value
DilutiveSecuritiesOptionsEarningsPerShareValue
0 USD
CY2013Q3 prph Dilutive Securities Options Earnings Per Share Value
DilutiveSecuritiesOptionsEarningsPerShareValue
0 USD
CY2014Q3 prph Dilutive Securities Options Earnings Per Share Value
DilutiveSecuritiesOptionsEarningsPerShareValue
0 USD
prph Dilutive Securities Options Earnings Share
DilutiveSecuritiesOptionsEarningsShare
0 shares
prph Dilutive Securities Options Earnings Share
DilutiveSecuritiesOptionsEarningsShare
0 shares
CY2013Q3 prph Dilutive Securities Options Earnings Share
DilutiveSecuritiesOptionsEarningsShare
447000 shares
CY2013Q3 prph Dilutive Securities Options Earnings Per Share
DilutiveSecuritiesOptionsEarningsPerShare
0
CY2014Q3 prph Dilutive Securities Options Earnings Per Share
DilutiveSecuritiesOptionsEarningsPerShare
0
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-193000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-7158000 USD
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
1236000 USD
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3216000 USD
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15819000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
17216000 shares
CY2013Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
16307000 shares
CY2014Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18208000 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
CY2013Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1264000 shares
CY2014Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1632500 shares
CY2014Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4266000 USD
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4064000 USD
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0005
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0005
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24696786 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21437059 shares
CY2014Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
9232817 shares
CY2013Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
5336053 shares
us-gaap Sales Revenue Net
SalesRevenueNet
15430000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
13098000 USD
CY2013Q3 us-gaap Sales Revenue Net
SalesRevenueNet
5949000 USD
CY2014Q3 us-gaap Sales Revenue Net
SalesRevenueNet
5130000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5346000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4816000 USD
CY2013Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2132000 USD
CY2014Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1620000 USD
us-gaap Gross Profit
GrossProfit
10084000 USD
us-gaap Gross Profit
GrossProfit
8282000 USD
CY2013Q3 us-gaap Gross Profit
GrossProfit
3817000 USD
CY2014Q3 us-gaap Gross Profit
GrossProfit
3510000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5163000 USD
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4724000 USD
CY2013Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1091000 USD
CY2014Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
875000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4521000 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6228000 USD
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1306000 USD
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1917000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
586000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
907000 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
181000 USD
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
356000 USD
us-gaap Operating Expenses
OperatingExpenses
10270000 USD
us-gaap Operating Expenses
OperatingExpenses
15436000 USD
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
2578000 USD
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
6725000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-186000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-7154000 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
1239000 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3215000 USD
us-gaap Interest And Other Income
InterestAndOtherIncome
2000 USD
us-gaap Interest And Other Income
InterestAndOtherIncome
3000 USD
CY2013Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
0 USD
CY2014Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
1000 USD
us-gaap Interest Expense
InterestExpense
9000 USD
us-gaap Interest Expense
InterestExpense
7000 USD
CY2013Q3 us-gaap Interest Expense
InterestExpense
3000 USD
CY2014Q3 us-gaap Interest Expense
InterestExpense
2000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-193000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7158000 USD
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1236000 USD
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3216000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2014Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Net Income Loss
NetIncomeLoss
-193000 USD
us-gaap Net Income Loss
NetIncomeLoss
-7158000 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
1236000 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-3216000 USD
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.01
us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.42
CY2013Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
0.08
CY2014Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.18
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
191000 USD
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4909000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
178000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
202000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
146000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
191000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-964000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1268000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1222000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1659000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1097000 USD
prph Increase Decrease In Accrued Marketing Costs
IncreaseDecreaseInAccruedMarketingCosts
-67000 USD
prph Increase Decrease In Accrued Marketing Costs
IncreaseDecreaseInAccruedMarketingCosts
319000 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-473000 USD
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-691000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
281000 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1478000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-324000 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-116000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
195000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4909000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
222000 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
4909000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3315000 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
751000 USD
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
ProPhase Labs, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0000868278
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
PRPH
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15463969 shares
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
3577000 USD
CY2013Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
CY2014Q3 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
3577000 USD
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.01
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.42
CY2013Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.08
CY2014Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.18
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
6000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
27000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
us-gaap Asset Impairment Charges
AssetImpairmentCharges
3600000 USD
CY2014Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
3600000 USD
prph Treasury Stock Acquired Pursuant To Settlement Agreement
TreasuryStockAcquiredPursuantToSettlementAgreement
0 USD
prph Treasury Stock Acquired Pursuant To Settlement Agreement
TreasuryStockAcquiredPursuantToSettlementAgreement
5105000 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
0 USD

Files In Submission

Name View Source Status
0001144204-14-067701-index-headers.html Edgar Link pending
0001144204-14-067701-index.html Edgar Link pending
0001144204-14-067701.txt Edgar Link pending
0001144204-14-067701-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
prph-20140930.xml Edgar Link completed
prph-20140930.xsd Edgar Link pending
prph-20140930_cal.xml Edgar Link unprocessable
prph-20140930_def.xml Edgar Link unprocessable
prph-20140930_lab.xml Edgar Link unprocessable
prph-20140930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v393070_10q.htm Edgar Link pending
v393070_ex31-1.htm Edgar Link pending
v393070_ex31-2.htm Edgar Link pending
v393070_ex32-1.htm Edgar Link pending
v393070_ex32-2.htm Edgar Link pending